Comparison of Six-Month Angiographic and Three-Year Outcomes After Sirolimus-Eluting Stent Implantation Versus Brachytherapy for Bare Metal In-Stent Restenosis

Seung Whan Lee, Seong Wook Park, Duk Woo Park, Se Whan Lee, Sang Hyun Kim, Jae Sik Jang, Yeong Hoon Jeong, Young Hak Kim, Cheol Whan Lee, Myeong Ki Hong, Seong Chul Yun, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To evaluate long-term effectiveness of sirolimus-eluting stent (SES) implantation for diffuse bare metal in-stent restenosis (ISR), we compared 6-month angiographic and long-term (3-year) clinical outcomes of SES implantation and intracoronary brachytherapy (ICBT). SES implantation for diffuse ISR was performed in 120 consecutive patients and their results were compared with those from 240 patients treated with β-radiation with balloons filled with rhenium-188 and mercaptoacetyltriglycine. The radiation dose was 15 or 18 Gy at a depth of 1.0 mm into the vessel wall. The primary end point was 3-year major adverse cardiac events including myocardial infarction, cardiac death, and target lesion revascularization. The 2 groups were similar in baseline clinical and angiographic characteristics. Lesion lengths were 25.1 ± 14.2 mm in the SES group and 24.5 ± 10.4 mm in the ICBT group (p = 0.15). In-stent acute gain was greater in the SES group than in the ICBT group (2.23 ± 0.62 vs 1.91 ± 0.54 mm, p <0.001). We obtained 6-month angiographic follow-up in 287 patients (79.7%). In-segment angiographic restenoses were 7.4% (7 of 94) in the SES group and 26.4% (51 of 193) in the ICBT group (p <0.05). Two myocardial infarctions (1 in each group) and 5 deaths (4 in SES group, 1 in ICBT group) occurred during 3-year follow-up. At 3 years, survival rates without target lesion revascularization (94.1 ± 2.2% vs 84.6 ± 2.3%, p = 0.011) and major adverse cardiac events (92.5 ± 2.4% vs 84.2 ± 2.4%, respectively, p = 0.03) were higher in the SES than in the ICBT group. In conclusion, compared with ICBT, SES implantation for diffuse ISR is more effective in decreasing recurrent restenosis and improving long-term outcomes.

Original languageEnglish
Pages (from-to)425-430
Number of pages6
JournalAmerican Journal of Cardiology
Volume100
Issue number3
DOIs
Publication statusPublished - 2007 Aug 1

Fingerprint

Brachytherapy
Sirolimus
Stents
Metals
Myocardial Infarction
Radiation
Survival Rate

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Seung Whan ; Park, Seong Wook ; Park, Duk Woo ; Lee, Se Whan ; Kim, Sang Hyun ; Jang, Jae Sik ; Jeong, Yeong Hoon ; Kim, Young Hak ; Lee, Cheol Whan ; Hong, Myeong Ki ; Yun, Seong Chul ; Kim, Jae Joong ; Park, Seung Jung. / Comparison of Six-Month Angiographic and Three-Year Outcomes After Sirolimus-Eluting Stent Implantation Versus Brachytherapy for Bare Metal In-Stent Restenosis. In: American Journal of Cardiology. 2007 ; Vol. 100, No. 3. pp. 425-430.
@article{37da83fe843b4991adbaaf82f4e2a8f9,
title = "Comparison of Six-Month Angiographic and Three-Year Outcomes After Sirolimus-Eluting Stent Implantation Versus Brachytherapy for Bare Metal In-Stent Restenosis",
abstract = "To evaluate long-term effectiveness of sirolimus-eluting stent (SES) implantation for diffuse bare metal in-stent restenosis (ISR), we compared 6-month angiographic and long-term (3-year) clinical outcomes of SES implantation and intracoronary brachytherapy (ICBT). SES implantation for diffuse ISR was performed in 120 consecutive patients and their results were compared with those from 240 patients treated with β-radiation with balloons filled with rhenium-188 and mercaptoacetyltriglycine. The radiation dose was 15 or 18 Gy at a depth of 1.0 mm into the vessel wall. The primary end point was 3-year major adverse cardiac events including myocardial infarction, cardiac death, and target lesion revascularization. The 2 groups were similar in baseline clinical and angiographic characteristics. Lesion lengths were 25.1 ± 14.2 mm in the SES group and 24.5 ± 10.4 mm in the ICBT group (p = 0.15). In-stent acute gain was greater in the SES group than in the ICBT group (2.23 ± 0.62 vs 1.91 ± 0.54 mm, p <0.001). We obtained 6-month angiographic follow-up in 287 patients (79.7{\%}). In-segment angiographic restenoses were 7.4{\%} (7 of 94) in the SES group and 26.4{\%} (51 of 193) in the ICBT group (p <0.05). Two myocardial infarctions (1 in each group) and 5 deaths (4 in SES group, 1 in ICBT group) occurred during 3-year follow-up. At 3 years, survival rates without target lesion revascularization (94.1 ± 2.2{\%} vs 84.6 ± 2.3{\%}, p = 0.011) and major adverse cardiac events (92.5 ± 2.4{\%} vs 84.2 ± 2.4{\%}, respectively, p = 0.03) were higher in the SES than in the ICBT group. In conclusion, compared with ICBT, SES implantation for diffuse ISR is more effective in decreasing recurrent restenosis and improving long-term outcomes.",
author = "Lee, {Seung Whan} and Park, {Seong Wook} and Park, {Duk Woo} and Lee, {Se Whan} and Kim, {Sang Hyun} and Jang, {Jae Sik} and Jeong, {Yeong Hoon} and Kim, {Young Hak} and Lee, {Cheol Whan} and Hong, {Myeong Ki} and Yun, {Seong Chul} and Kim, {Jae Joong} and Park, {Seung Jung}",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.amjcard.2007.03.040",
language = "English",
volume = "100",
pages = "425--430",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

Comparison of Six-Month Angiographic and Three-Year Outcomes After Sirolimus-Eluting Stent Implantation Versus Brachytherapy for Bare Metal In-Stent Restenosis. / Lee, Seung Whan; Park, Seong Wook; Park, Duk Woo; Lee, Se Whan; Kim, Sang Hyun; Jang, Jae Sik; Jeong, Yeong Hoon; Kim, Young Hak; Lee, Cheol Whan; Hong, Myeong Ki; Yun, Seong Chul; Kim, Jae Joong; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 100, No. 3, 01.08.2007, p. 425-430.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of Six-Month Angiographic and Three-Year Outcomes After Sirolimus-Eluting Stent Implantation Versus Brachytherapy for Bare Metal In-Stent Restenosis

AU - Lee, Seung Whan

AU - Park, Seong Wook

AU - Park, Duk Woo

AU - Lee, Se Whan

AU - Kim, Sang Hyun

AU - Jang, Jae Sik

AU - Jeong, Yeong Hoon

AU - Kim, Young Hak

AU - Lee, Cheol Whan

AU - Hong, Myeong Ki

AU - Yun, Seong Chul

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 2007/8/1

Y1 - 2007/8/1

N2 - To evaluate long-term effectiveness of sirolimus-eluting stent (SES) implantation for diffuse bare metal in-stent restenosis (ISR), we compared 6-month angiographic and long-term (3-year) clinical outcomes of SES implantation and intracoronary brachytherapy (ICBT). SES implantation for diffuse ISR was performed in 120 consecutive patients and their results were compared with those from 240 patients treated with β-radiation with balloons filled with rhenium-188 and mercaptoacetyltriglycine. The radiation dose was 15 or 18 Gy at a depth of 1.0 mm into the vessel wall. The primary end point was 3-year major adverse cardiac events including myocardial infarction, cardiac death, and target lesion revascularization. The 2 groups were similar in baseline clinical and angiographic characteristics. Lesion lengths were 25.1 ± 14.2 mm in the SES group and 24.5 ± 10.4 mm in the ICBT group (p = 0.15). In-stent acute gain was greater in the SES group than in the ICBT group (2.23 ± 0.62 vs 1.91 ± 0.54 mm, p <0.001). We obtained 6-month angiographic follow-up in 287 patients (79.7%). In-segment angiographic restenoses were 7.4% (7 of 94) in the SES group and 26.4% (51 of 193) in the ICBT group (p <0.05). Two myocardial infarctions (1 in each group) and 5 deaths (4 in SES group, 1 in ICBT group) occurred during 3-year follow-up. At 3 years, survival rates without target lesion revascularization (94.1 ± 2.2% vs 84.6 ± 2.3%, p = 0.011) and major adverse cardiac events (92.5 ± 2.4% vs 84.2 ± 2.4%, respectively, p = 0.03) were higher in the SES than in the ICBT group. In conclusion, compared with ICBT, SES implantation for diffuse ISR is more effective in decreasing recurrent restenosis and improving long-term outcomes.

AB - To evaluate long-term effectiveness of sirolimus-eluting stent (SES) implantation for diffuse bare metal in-stent restenosis (ISR), we compared 6-month angiographic and long-term (3-year) clinical outcomes of SES implantation and intracoronary brachytherapy (ICBT). SES implantation for diffuse ISR was performed in 120 consecutive patients and their results were compared with those from 240 patients treated with β-radiation with balloons filled with rhenium-188 and mercaptoacetyltriglycine. The radiation dose was 15 or 18 Gy at a depth of 1.0 mm into the vessel wall. The primary end point was 3-year major adverse cardiac events including myocardial infarction, cardiac death, and target lesion revascularization. The 2 groups were similar in baseline clinical and angiographic characteristics. Lesion lengths were 25.1 ± 14.2 mm in the SES group and 24.5 ± 10.4 mm in the ICBT group (p = 0.15). In-stent acute gain was greater in the SES group than in the ICBT group (2.23 ± 0.62 vs 1.91 ± 0.54 mm, p <0.001). We obtained 6-month angiographic follow-up in 287 patients (79.7%). In-segment angiographic restenoses were 7.4% (7 of 94) in the SES group and 26.4% (51 of 193) in the ICBT group (p <0.05). Two myocardial infarctions (1 in each group) and 5 deaths (4 in SES group, 1 in ICBT group) occurred during 3-year follow-up. At 3 years, survival rates without target lesion revascularization (94.1 ± 2.2% vs 84.6 ± 2.3%, p = 0.011) and major adverse cardiac events (92.5 ± 2.4% vs 84.2 ± 2.4%, respectively, p = 0.03) were higher in the SES than in the ICBT group. In conclusion, compared with ICBT, SES implantation for diffuse ISR is more effective in decreasing recurrent restenosis and improving long-term outcomes.

UR - http://www.scopus.com/inward/record.url?scp=34447634127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447634127&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.03.040

DO - 10.1016/j.amjcard.2007.03.040

M3 - Article

C2 - 17659922

AN - SCOPUS:34447634127

VL - 100

SP - 425

EP - 430

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -